Philogen SpA receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Philogen SpA (PHIL)
Philogen SpA stock price live, this page displays BIT PHIL stock exchange data. View the PHIL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Philogen SpA real time stock price chart below.
What Is the Philogen SpA Stock Price Today?
The Philogen SpA stock price today is 21.20.
What Is the Stock Symbol for Philogen SpA?
The stock symbol for Philogen SpA is "PHIL."
What Stock Exchange Does Philogen SpA Trade On?
Philogen SpA is listed and trades on the Milan stock exchange.
Is Philogen SpA a Good Stock to Buy?
Determining whether Philogen SpA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHIL quote. (ISIN: IT0005373789)
What Is the Philogen SpA Stock Price Today?
The Philogen SpA stock price today is 21.20.
What Is the Stock Symbol for Philogen SpA?
The stock symbol for Philogen SpA is "PHIL."
What Stock Exchange Does Philogen SpA Trade On?
Philogen SpA is listed and trades on the Milan stock exchange.
Is Philogen SpA a Good Stock to Buy?
Determining whether Philogen SpA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHIL quote. (ISIN: IT0005373789)
21.20
+0.35(+1.68%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.70
21.30
52 wk Range
19.56
27.80
PHIL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.7021.30
52 wk Range
19.5627.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.30%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.30%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHIL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
23.00
Upside
+8.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
- Philogen SpA receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Philogen S.p.A. receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Philogen SpA receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Philogen SpA receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in Phase II trial for the treatment of non-small cell lung cancer. It is also developing Dekavil (F8IL10), an anti-inflammatory product in Phase II trial for the treatment of chronic inflammatory disorders; Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12, which is in Phase I trial to treat advanced solid tumors; OncoFAP radio conjugates, a small molecule radiotracer with ultra high affinity for fibroblast activation protein in Phase I trial for diagnostic and therapeutic applications of metastatic solid tumors; OncoACP3, a small molecule radiotracer with ultra high-affinity for acid phosphatase 3 in Phase I trial for diagnostic and therapeutic applications for prostate cancer; OncoCAIX, a small molecule radiotracer in Phase 1 trial for the detection of Carbonic Anhydrase IX (CAIX) expressed in renal cell carcinoma and other hypoxic tumors; and OncoFAP-GlyPro-MMAE, a small molecule drug conjugate with ultra-high affinity for fibroblast activation protein in preclinical trial for the treatment of solid tumors. Philogen S.p.A. was founded in 1996 and is headquartered in Siena, Italy.
Philogen SpA Earnings Call Summary for H2/2025
- Philogen reported EUR 230M net profit for 2025 with EUR 380M cash reserves; approved EUR 0.70 per share dividend and 35% share buyback authorization.
- Product pipeline advanced with Nidlegy and Fibromun showing clinical progress; OncoACP3 partnership with Bristol Myers Squibb/RayzeBio to drive revenue.
- Company maintains diversified revenue from milestones, service activities, and partnerships; expects modest spending increase to EUR 4-5M monthly in 2026.
- Management emphasizes pragmatic approach focusing on financially viable trials with positive outcome expectations while maintaining strong cash position.
Last Updated: 2026-03-30, 11:38 a/m
Read Full TranscriptCompare PHIL to Peers and Sector
Metrics to compare | PHIL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHILPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.8x | −0.8x | −0.5x | |
PEG Ratio | 0.01 | 0.02 | 0.00 | |
Price/Book | 2.3x | 3.4x | 2.6x | |
Price / LTM Sales | 2.7x | 4.0x | 3.2x | |
Upside (Analyst Target) | 8.5% | 131.6% | 45.7% | |
Fair Value Upside | Unlock | 21.3% | 4.8% | Unlock |
Analyst Ratings
1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 23.00
(+8.49% Upside)
Earnings
Latest Release
Apr 09, 2026
EPS / Forecast
6.04 / --
Revenue / Forecast
311.2M / --
People Also Watch
FAQ
What Is the Philogen SpA (PHIL) Stock Price Today?
The Philogen SpA stock price today is 21.20 EUR.
What Stock Exchange Does Philogen SpA Trade On?
Philogen SpA is listed and trades on the Milan Stock Exchange.
What Is the Stock Symbol for Philogen SpA?
The stock symbol for Philogen SpA is "PHIL."
Does Philogen SpA Pay Dividends? What’s The Current Dividend Yield?
The Philogen SpA dividend yield is 3.3%.
What Is the Philogen SpA Market Cap?
As of today, Philogen SpA market cap is 839.86M EUR.
What Is Philogen SpA's Earnings Per Share (TTM)?
The Philogen SpA EPS (TTM) is 5.70.
From a Technical Analysis Perspective, Is PHIL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Philogen SpA Stock Split?
Philogen SpA has split 0 times.
How Many Employees Does Philogen SpA Have?
Philogen SpA has 214 employees.
What is the current trading status of Philogen SpA (PHIL)?
As of Apr 16, 2026, Philogen SpA (PHIL) is trading at a price of 21.20 EUR, with a previous close of 20.85 EUR. The stock has fluctuated within a day range of 20.70 EUR to 21.30 EUR, while its 52-week range spans from 19.56 EUR to 27.80 EUR.
What Is Philogen SpA (PHIL) Price Target According to Analysts?
The average 12-month price target for Philogen SpA is 23.00 EUR, with a high estimate of 27 EUR and a low estimate of 19 EUR. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +8.49% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.